Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HRS-7535 in Moderate Renal Insufficiency
NCT06132204Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HRS-7535 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Started Dec 2023; status: completed.
02
Drugs
HRS-7535
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06132204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132204.